I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer

被引：0
|
作者：
Haiyun Wang
Douglas Yee
机构：
[1] University of Minnesota,Masonic Cancer Center
来源：
Current Breast Cancer Reports | 2019年 / 11卷
关键词：
I-SPY 2; Breast cancer; Neoadjuvant chemotherapy; Pathological complete response; Adaptive randomization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：303 / 310
页数：7
相关论文
共 50 条
  • [1] I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer
    Wang, Haiyun
    Yee, Douglas
    CURRENT BREAST CANCER REPORTS, 2019, 11 (04) : 303 - 310
  • [2] Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
    Onishi, Natsuko
    Li, Wen
    Gibbs, Jessica
    Wilmes, Lisa J.
    Nguyen, Alex
    Jones, Ella F.
    Arasu, Vignesh
    Kornak, John
    Joe, Bonnie N.
    Esserman, Laura J.
    Newitt, David C.
    Hylton, Nola M.
    TOMOGRAPHY, 2020, 6 (02) : 77 - 85
  • [3] Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)
    Cureton, Elizabeth L.
    Yau, Christina
    Alvarado, Michael D.
    Krontiras, Helen
    Ollila, David W.
    Ewing, Cheryl A.
    Monnier, Sindy
    Esserman, Laura J.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (09) : 2889 - 2896
  • [4] Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study
    Magbanua, Mark Jesus M.
    van 't Veer, Laura
    Clark, Amy S.
    Chien, A. Jo
    Boughey, Judy C.
    Han, Hyo S.
    Wallace, Anne
    Beckwith, Heather
    Liu, Minetta C.
    Yau, Christina
    Wileyto, E. Paul
    Ordonez, Andrea
    Solanki, Tulasi I.
    Hsiao, Feng
    Lee, Jen Chieh
    Basu, Amrita
    Swigart, Lamorna Brown
    Perlmutter, Jane
    Delson, Amy L.
    Bayne, Lauren
    Deluca, Shannon
    Yee, Stephanie S.
    Carpenter, Erica L.
    Esserman, Laura J.
    Park, John W.
    Chodosh, Lewis A.
    DeMichele, Angela
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 198 (02) : 383 - 390
  • [5] Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study
    Mark Jesus M. Magbanua
    Laura van ‘t Veer
    Amy S. Clark
    A. Jo Chien
    Judy C. Boughey
    Hyo S. Han
    Anne Wallace
    Heather Beckwith
    Minetta C. Liu
    Christina Yau
    E. Paul Wileyto
    Andrea Ordonez
    Tulasi I. Solanki
    Feng Hsiao
    Jen Chieh Lee
    Amrita Basu
    Lamorna Brown Swigart
    Jane Perlmutter
    Amy L. Delson
    Lauren Bayne
    Shannon Deluca
    Stephanie S. Yee
    Erica L. Carpenter
    Laura J. Esserman
    John W. Park
    Lewis A. Chodosh
    Angela DeMichele
    Breast Cancer Research and Treatment, 2023, 198 : 383 - 390
  • [6] Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program
    Das, Sonya
    Lo, Andrew W.
    CONTEMPORARY CLINICAL TRIALS, 2017, 62 : 168 - 174
  • [7] Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657)
    Clark, Amy S.
    Chen, Jinbo
    Kapoor, Shiv
    Friedman, Claire
    Mies, Carolyn
    Esserman, Laura
    DeMichele, Angela
    CANCER MEDICINE, 2014, 3 (03): : 693 - 701
  • [8] Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial
    Wang, Haiyun
    Yee, Douglas
    Potter, David
    Jewett, Patricia
    Yau, Christina
    Beckwith, Heather
    Watson, Allison
    O'Grady, Nicholas
    Wilson, Amy
    Brain, Susie
    Pohlmann, Paula
    Blaes, Anne
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (03) : 589 - 597
  • [9] Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial
    Haiyun Wang
    Douglas Yee
    David Potter
    Patricia Jewett
    Christina Yau
    Heather Beckwith
    Allison Watson
    Nicholas O’Grady
    Amy Wilson
    Susie Brain
    Paula Pohlmann
    Anne Blaes
    Breast Cancer Research and Treatment, 2024, 204 : 589 - 597
  • [10] Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
    Li, Wen
    Newitt, David C.
    Gibbs, Jessica
    Wilmes, Lisa J.
    Jones, Ella F.
    Arasu, Vignesh A.
    Strand, Fredrik
    Onishi, Natsuko
    Nguyen, Alex Anh-Tu
    Kornak, John
    Joe, Bonnie N.
    Price, Elissa R.
    Ojeda-Fournier, Haydee
    Eghtedari, Mohammad
    Zamora, Kathryn W.
    Woodard, Stefanie A.
    Umphrey, Heidi
    Bernreuter, Wanda
    Nelson, Michael
    Church, An Ly
    Bolan, Patrick
    Kuritza, Theresa
    Ward, Kathleen
    Morley, Kevin
    Wolverton, Dulcy
    Fountain, Kelly
    Lopez-Paniagua, Dan
    Hardesty, Lara
    Brandt, Kathy
    McDonald, Elizabeth S.
    Rosen, Mark
    Kontos, Despina
    Abe, Hiroyuki
    Sheth, Deepa
    Crane, Erin P.
    Dillis, Charlotte
    Sheth, Pulin
    Hovanessian-Larsen, Linda
    Bang, Dae Hee
    Porter, Bruce
    Oh, Karen Y.
    Jafarian, Neda
    Tudorica, Alina
    Niell, Bethany L.
    Drukteinis, Jennifer
    Newell, Mary S.
    Cohen, Michael A.
    Giurescu, Marina
    Berman, Elise
    Lehman, Constance
    NPJ BREAST CANCER, 2020, 6 (01)
12345